Britain Has Chosen Big Pharma Over the NHS
Britain has accepted a trade linked medicines pricing reset that makes the NHS pay more. NICE’s new chief executive has warned that paying more to satisfy Trump style demands is a huge backwards step because higher drug spend means higher taxes or NHS cuts. This analysis explains what the government agreed, why the policy is fracturing, and how the NHS cost can be estimated.